Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

. 2025 Dec 31 ; 15 (1) : 217. [epub] 20251231

Status In-Process Jazyk angličtina Země Spojené státy americké Médium electronic

Typ dokumentu dopisy

Perzistentní odkaz   https://www.medvik.cz/link/pmid41476142
E-zdroje Online Plný text
Odkazy

PubMed 41476142
PubMed Central PMC12756333
DOI 10.1038/s41408-025-01444-0
PII: 10.1038/s41408-025-01444-0
Knihovny.cz E-zdroje

[Image: see text]

Zobrazit více v PubMed

Brunner AM, Leitch HA, van de Loosdrecht AA, Bonadies N. Management of patients with lower-risk myelodysplastic syndromes. Blood Cancer J. 2022;12:166. PubMed DOI PMC

Garcia-Manero G. Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations. Lancet Haematol. 2023;10:e71–e8. PubMed DOI

Jain AG, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, et al. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia. Haematologica. 2024;109:2157–64. PubMed PMC

Platzbecker U. Treatment of MDS. Blood. 2019;133:1096–107. PubMed DOI

Ramanathan R, Xie Y, Badar T, Zeidan AM, Patel SA. Contemporary management paradigms and emerging therapeutics for myelodysplastic syndromes/neoplasms. Br J Haematol. 2025;206:1571–81. PubMed DOI

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for MyelodysplasticSyndromes V.1.2026. © National Comprehensive Cancer Network, Inc. 2026. Accessed October 22.

Fenaux P, Santini V, Spiriti MAA, Giagounidis A, Schlag R, Radinoff A, et al. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-alpha in anemic patients with low-risk MDS. Leukemia. 2018;32:2648–58. PubMed DOI PMC

Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, et al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;403:249–60. PubMed DOI

Apuri S, Al Ali N, Padron E, Lancet JE, List AF, Komrokji RS. Evidence for selective benefit of sequential treatment with hypomethylating agents in patients with myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2017;17:211–4. PubMed DOI

Steensma DP, Fenaux P, Van Eygen K, Raza A, Santini V, Germing U, et al. Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study. J Clin Oncol. 2021;39:48–56. PubMed DOI

Lennox AL, Sun L, Huang F, Behrs MK, Kleiman R, Xue H, et al. Low proarrhythmic risk of imetelstat, a novel oligonucleotide telomerase inhibitor: a translational analysis. Clin Transl Sci. 2025;18:e70169. PubMed DOI PMC

De Swart L, Crouch S, Hoeks M, Smith A, Langemeijer S, Fenaux P, et al. Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. Haematologica. 2020;105:632–9. PubMed DOI PMC

Lee J, Kim J, Cho HJ, Baek DW, Ham JY, Chang SH, et al. PB2011: Tranfusion burden is an important prognostic factor in lower-risk myelodysplastic syndrome. Hemasphere. 2023;7:e657279e.

Komrokji RS, Supina D, Navada S, Potluri R, Tyagi R, Werwath T, et al. Transfusion independence corresponds with survival in patients with lower-risk myelodysplastic syndrome: real-world evidence from United States insurance claims. Clin Lymphoma Myeloma Leuk. 2025;25:e740-e9. PubMed

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace